Daniel Afar is a seasoned professional with extensive experience in oncology and therapeutic antibody development. Currently, Daniel serves as Vice President of Project Leadership for Oncology Early Development at AbbVie since August 2013, overseeing the strategy and execution of OED programs and supervising project leaders in immuno-oncology clinical biomarkers. Previously, Daniel held key roles at Merck, Facet Biotech, PDL BioPharma, EOS Biotechnology, and Agensys, where leadership involved directing clinical research and early development programs for therapeutic antibodies across various disease areas, including notable contributions to the elotuzumab and pembrolizumab programs. Daniel's academic background includes a BSc and MSc in Biology and Pharmacology from McGill University, a Post-Doc in Molecular Biology from UCLA, and a PhD in Biochemistry from the University of Ottawa.
This person is not in the org chart
This person is not in any teams
This person is not in any offices